SNHG10 and osteosarcoma: SNHG10 has been identified as oncogenic in bladder cancer (Jiang et al., 2018), hepatocellular carcinoma (Lan et al., 2019), osteosarcoma (He et al., 2020), glioma (Jin et al., 2020), non–small cell lung cancer (Zhang et al., 2020b; Liang et al., 2020), acute myeloid leukemia (Xiao et al., 2021), and gastric cancer (Yuan et al., 2021; Zhang et al., 2021).